Ocular Pain - Pipeline Review, H2 2016

  • ID: 3876133
  • Report
  • 70 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Ocular Therapeutix, Inc.
  • Sylentis S.A.U.
  • MORE
Ocular Pain - Pipeline Review, H2 2016

Summary

‘Ocular Pain - Pipeline Review, H2 2016’, provides an overview of the Ocular Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Pain
- The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects
- The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ocular Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ocular Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Ocular Therapeutix, Inc.
  • Sylentis S.A.U.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Ocular Pain Overview

Therapeutics Development

Pipeline Products for Ocular Pain - Overview

Ocular Pain - Therapeutics under Development by Companies

Ocular Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Ocular Pain - Products under Development by Companies

Ocular Pain - Companies Involved in Therapeutics Development

D. Western Therapeutics Institute, Inc.

InSite Vision Incorporated

Kala Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

Reata Pharmaceuticals, Inc.

Sylentis S.A.U.

Valeant Pharmaceuticals International, Inc.

Ocular Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(bromfenac sodium + dexamethasone acetate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bromfenac sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Ocular Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketorolac tromethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

loteprednol etabonate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

loteprednol etabonate next generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-71 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-72 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omaveloxolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RX-10045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYL-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ocular Pain - Dormant Projects

Ocular Pain - Product Development Milestones

Featured News & Press Releases

Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite

Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome

Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit

Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite

Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery

May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery

Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite

Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery

Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery

Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery

Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery

Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery

Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling

Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Ocular Pain, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Ocular Pain - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016

Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2016

Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2016

Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H2 2016

Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2016

Ocular Pain - Pipeline by Sylentis S.A.U., H2 2016

Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Ocular Pain - Dormant Projects, H2 2016 59List of Figures

Number of Products under Development for Ocular Pain, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Ocular Therapeutix, Inc.
  • Sylentis S.A.U.
  • MORE
According to ourrecently published report 'Ocular Pain – Pipeline Review, H2 2016'; Ocular Pain pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

Furthermore, the publisher says; Ocular Pain Ocular pain occurs on the surface of eye. Ocular pain is usually caused by irritation from a foreign object, infection, or trauma. Symptoms include light sensitivity, discharge, which can be clear, or thick and colored (pus), decreased vision, headache and conjunctivitis (red itchy eyes). Treatment includes antibiotics, antihistamines and corticosteroids

The report 'Ocular Pain – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. Currently, The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 4, 3 and 6 respectively.
Note: Product cover images may vary from those shown
5 of 6
D. Western Therapeutics Institute, Inc.
InSite Vision Incorporated
Kala Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Reata Pharmaceuticals, Inc.
Sylentis S.A.U.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll